ClinicalTrials.gg
CompletedNCT05884554Updated Sep 19, 2024

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

A Phase 1 interventional study of PF-07817883 in COVID-19, sponsored by Pfizer. Completed at 6 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.

Enrollment
20th of 41
21 · median 20
Started
2023
with 11 others
Phase 1
25 of 69
none open now
Registered
41st of 69
by date

Among the 69 studies in COVID-19 by Pfizer, this one is the 20th largest by enrollment of the 41 interventional ones that give a count, is one of 12 that started in 2023, is one of 25 in phase 1, and was the 41st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in COVID-19 by Pfizer, or all of them as a file.
02

Study summary

The purpose of the study is to learn about the safety of PF-07817883 and how PF-07817883 is processed in the body of adult participants. These participants will have different degrees of loss of liver function. Participants with mild, moderate, severe or no loss of liver function will be enrolled in 4 groups.

This study is seeking participants who:

  • are male or female of 18- 75 years of age
  • either have different amounts of damage to liver function or for one of the groups, no damage
  • willing to follow the requirements of the study including stay at clinic for 6 nights and 7 days

About, 6-8 participants will be enrolled in group 1 (participants without loss of liver function) and group 3 (participants with moderate loss of liver function). In group 4 (participants with severe loss of function), around 4 to 8 participants will be enrolled. Participants in group 2 (mild loss of function) will only be enrolled after review of the data from groups 3 and 4.

If participants consent to participate in the study, it may take up to 4 weeks to complete all the tests to confirm if they are eligible to participate in the study. If they seem to be eligible for the study, participants will be admitted to a clinic research unit (CRU) at least 12 hours before dosing. On Day 1, participants will receive a single dose of study medicine (Day 1). A series of blood samples will be collected before and after dosing. Participants will be discharged from the CRU on Day 6. A follow-up phone call (on CRU visit, if needed), will occur 28-35 days after dosing.

The whole study will last for a minimum of 5 weeks and a maximum of 10 weeks.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Hepatic Impairment
  • COVID-19
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (HI Cohorts Only): Stable HI that meets criteria for Class A or B of the classification;
  • (all Cohorts): of 17.5 to 38.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption Additional Exclusion Criteria for HI Cohorts Only
  • Limited predicted
  • Hepatic dysfunction secondary to acute ongoing hepatocellular process.
  • Signs of clinically active Grade 2, 3 or 4 hepatic encephalopathy.
  • Severe ascites and/or pleural effusion
  • History of kidney, liver, or heart transplantation.
  • Persistent severe, uncontrolled hypertension.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Cohort 1

    No hepatic impairment

    Drug: PF-07817883

  • Experimental
    Cohort 2

    Mild hepatic impairment

    Drug: PF-07817883

  • Experimental
    Cohort 3

    Moderate hepatic impairment

    Drug: PF-07817883

  • Experimental
    Cohort 4

    Severe hepatic impairment

    Drug: PF-07817883

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of PF-07817883

    Plasma PF-07817883 PK parameters

    Time frame: Day 1 to Day 6

  2. Area Under the Plasma Concentration-time Profile from Time Zero to Extrapolated Infinite Time (AUCinf)

    Plasma PF-07817883 PK parameter

    Time frame: Day 1 to Day 6

  3. Area Under the Plasma Concentration-time Profile from Time Zero to the Time of the Last Quantifiable Concentration (AUClast)

    (Optional) Plasma PF-07817883 parameter

    Time frame: Day 1 to Day 6

Secondary outcomes

  1. Number of Participants with Non-Serious Adverse Events

    Safety Parameters

    Time frame: Screening to Day 35

  2. Number of Participants with Treatment Emergent Adverse Events

    Safety Parameters

    Time frame: Day 1 to Day 35

  3. Number of Participants with Clinically Significant ECG Abnormalities

    ECG parameters include QTcF, QRS, RR interval, PR interval, and Heart Rate

    Time frame: Day 1 to Day 6

  4. Number of Participants with Clinically Significant Abnormal Vital Signs

    Vital Signs parameters include diastolic blood pressure, systolic blood pressure, and pulse rate

    Time frame: Day 1 to Day 6

  5. Number of Participants with Clinically Significant Abnormal Laboratory Values

    Blood hematology and Chemistry and Urinalysis

    Time frame: Baseline to Day 6

  6. Number of Participants with Serious Adverse Events

    Safety Parameters

    Time frame: Screening to Day 35

07

Study locations

6 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • National Institute of Clinical Research
    Garden Grove, California 92844, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Research Centers of America ( Hollywood )
    Hollywood, Florida 33024, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Genesis Clinical Research, LLC
    Tampa, Florida 33603, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jun 2024, 12 months.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 12 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2023
First posted
Jun 1, 2023
StartActual
Jun 15, 2023
Primary completionActual
Jun 27, 2024
CompletionActual
Jun 27, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05884554
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 1, 2023
Start date
Jun 15, 2023
Primary completion
Jun 27, 2024
Completion
Jun 27, 2024
Last update
Sep 19, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuzatrelvir

Start the discussion